

April 4, 2025

Company name	CellSource Co., Ltd.
Name of representative	Takashi Sawada, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information for inquiries	Tomohiro Iga, Executive Officer and General Manager of Corporate Division Tel: +81-3-6455-5308

CellSource Transfers Patent Application for Animal Regenerative Medicine to Anicom Specialty Medical Institute

CellSource Co., Ltd. (Representative Director and CEO: Takashi Sawada, hereinafter referred to as the “Company”) is pleased to announce that it will transfer a portion of its patent applications related to canine platelet-derived growth factor (cPGF) therapy, a form of animal regenerative medicine, to Anicom Specialty Medical Institute Inc. (Representative Director: Ryo Horie, hereinafter referred to as “Anicom Specialty Medical Institute”).

The cPGF therapy is a cell-free and freeze-dried form of platelet-rich plasma (PRP) derived from the blood of canine donors. It is expected to promote tissue repair and reduce pain when applied topically. In September 2023, the Company joined the Animal Regenerative Medicine Technology Research Consortium (PARM), which includes Anicom Specialty Medical Institute, Anicom Insurance Inc., and animal hospitals nationwide, to advance research on regenerative medicine in veterinary care and manufacturing technology. As of April 2024, cPGF therapy has been offered at veterinary hospitals operated by Anicom Specialty Medical Institute within the Anicom Animal Hospital Group.

The lifespan of companion animals, such as dogs, continues to increase, and the demand for veterinary care is expected to rise further. The Company believes that Anicom Specialty Medical Institute is the optimal operator for utilizing this patented technology to treat high-need conditions in veterinary medicine, and this transfer is expected to bring benefits to society.

This transaction includes the transfer of 99% of the rights to the patent application related to cPGF. While the Company will continue to cooperate with Anicom Specialty Medical Institute as a co-owner of the patent application, it plans to withdraw from PARM.

This move is part of the Company's commitment to optimizing resource allocation, as outlined in the CellSource Vision announced in December 2024, focusing on accelerating its concentration on the

orthopedic field. The revenue from this transfer is expected to be recorded in the second quarter of the fiscal year ending October 31, 2025.

*1: Anicom Holdings, Inc. "Anicom Pet Family White Paper 2023."

https://www.anicom-page.com/hakusho/book/pdf/book_202312.pdf

CellSource Co., Ltd.

CellSource specializes in advancing the industrialization of regenerative medicine, providing services such as processing adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3240004) in accordance with the Act on the Safety of Regenerative Medicine, it has handled over 100,000 cell-related procedures. With a wealth of experience, it strives to offer reliable services to medical institutions and contribute to research and technological development.

Representative Chairman of the Board: Masayuki Yamakawa

Representative director and CEO: Takashi Sawada

Listed Market: Tokyo Stock Exchange, Prime Market (Securities Code: 4880)

Location: Shibuya Cast 11F, 1-23-21 Shibuya, Shibuya-ku, Tokyo

URL: <https://www.cellsources.co.jp/en/>

Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete.

In the event of any translation error or misunderstanding, the original Japanese version shall prevail.